12 Sep 2022 ImmuneWatch secures a VLAIO grant to tailor their technology to vaccine developers Member news
07 Sep 2022 New three-year BIMZELX®▼ (bimekizumab) data reinforce long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis Member news
31 Aug 2022 reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration Member news
22 Jun 2022 Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies Member news
25 May 2022 CureVac partners with myNEO to identify novel antigen targets for mRNA-based cancer vaccine development Member news
06 May 2022 Ziphius Vaccines and Ghent University publish promising data from self-amplifying RNA platform in Molecular Therapy Member news
04 May 2022 New study led by Memorial Sloan Kettering Cancer Center (NY, US) shows Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods Member news
03 May 2022 reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Member news
27 Apr 2022 Kantify and I-Stem Use Artificial Intelligence to discover a promising therapy against a rare disease Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
